KINAXO enters into US and Japanese partnerships to introduce its Cellular Target Profiling Service
Advertisement
KINAXO Biotechnologies GmbH announced that it has entered into strategic sales and marketing partnerships with BioCatalyst International and BioFocus DPI to support the introduction of KINAXO’s proprietary Cellular Target Profiling™ Service within the US and Japanese market.
According to the company, the KINAXO Cellular Target Profiling Service enables drug developers to determine the native cellular protein interactions of small molecule compounds in a physiological setting. This provides significant benefits to any drug development program, since knowledge of the compound’s proteome-wide on/off-target activities supports the prediction of its performance in clinical trials.
KINAXO chose to partner with BioCatalyst and BioFocus DPI due to their hands-on experience in supporting high value drug discovery services. Both partners will work closely with the KINAXO management and scientific team to ensure qualified, personalized support in the US and Japan.
Dr. Andreas Jenne, KINAXO’s CEO commented: “The pharmaceutical industry is very much a global industry and thus it is critical to rapidly establish a presence in the major markets. Our sophisticated services require that we partner with organizations that fully understand both the high value information we offer and the particular needs of drug developers. We are very excited about working with BioCatalyst and BioFocus DPI to better serve our customers in the US and Japan.”
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
InterMed Discovery achieves Proof-of-Principle for IMD-026260 - Small molecule anti-cancer drug candidate based on Hif-1 modulation
Large international study finds memory in adults impacted by versions of 4 genes - Second study identifies brain-development genes associated with intracranial volume
Evolva acquires resveratrol programme from Fluxome
Network that plays crucial role in cell function and disease
Celera Genomics Receives NIH Grant to Develop and Commercialize Avian Flu Diagnostic Test